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background:  Women have longer QTc intervals than men, and female sex is an independent risk for drug-induced QTc prolongation. To 
minimize the risk of QTc prolongation, dofetilide dosing is based on creatinine clearance (CrCl) by the Cockroft-Gault equation. This project 
tests the hypothesis that women need a different dosing algorithm than men.
Methods:  Patients admitted to Duke Medical Center 1/1/2005 to 12/31/2011 for initiation of 500mcg dofetilide twice daily were included. 
Demographics, co-morbidities, labs, and ECG data during the hospitalization were obtained through chart abstraction. Female and male 
patients were matched 1:1 based on age and CrCl, and rates of dofetilide discontinuation and dose reductions were compared between 
men and women using Chi-square test.
results:  Among 178 matched men and women, the mean age was 61 ± 11 years for women and 61 ± 11 years for men (p=1.0), and the 
mean CrCl was 109 ± 37 mL/min and 109 ± 33 mL/min for women and men, respectively (p=0.92). During dofetilide initiation, women were 
more likely than matched male patients to have their dofetilide dose reduced or stopped (55% vs 34%, p= 0.004) (Figure). Women had a 
higher incidence of QTc prolongation than men (43% vs 28%, p=0.04).
Conclusion:  More than half of women that started on 500mcg twice daily of dofetilide had their doses decreased or the medication 
discontinued, mostly due to QTc prolongation. Despite cohorts that were matched on CrCl, women were less likely than men to be able to 
tolerate a 500mcg dose of dofetilide.
